Abstract
The objective of this study was to examine the associations between aromatase inhibitor therapy and hair loss or hair thinning among female breast cancer survivors. Data were analyzed from 851 female breast cancer survivors who responded to a hospital registry-based survey. Data on hair loss, hair thinning, demographic characteristics, and health habits were based on self-report; data on aromatase inhibitor therapy were collected on the survey and verified using medical record review. Logistic regression was used to estimate the odds ratios (ORs) and 95 % confidence intervals (CIs) for the associations between aromatase inhibitor therapy and the hair outcome variables adjusted for potential confounders, including age and chemotherapy treatment. The results showed that 22.4 % of the breast cancer survivors reported hair loss and 31.8 % reported hair thinning. In the confounder-adjusted analyses, breast cancer survivors who were within 2 years of starting aromatase inhibitor treatment at the time of survey completion were approximately two and a half times more likely to report reporting hair loss (OR 2.55; 95 % CI 1.19–5.45) or hair thinning (OR 2.33; 95 % CI 1.10–4.93) within the past 4 weeks compared to those who were never treated with an aromatase inhibitor. Current aromatase inhibitor use for two or more years at the time of the survey and prior use were significantly associated with hair thinning (current users, ≥2 years: OR 1.86; prior users: OR 1.62), but not hair loss. Findings from this study suggest that aromatase inhibitor use is associated with an increased risk of hair loss and hair thinning independent of chemotherapy and age; these side effects are likely due to the substantial decrease in estrogen concentrations resulting from treatment with this drug. Future research should focus on examining these associations in a prospective manner using more detailed and objective measures of hair loss and thinning.
Similar content being viewed by others
References
Brodie AM, Njar VC (1998) Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol 66:1–10
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462
Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757
Jones SE, Cantrell J, Vukelja S, Pippen J, O’Shaughnessy J, Blum JL et al (2007) Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol 25:4765–4771
Gallicchio L, MacDonald R, Wood B, Rushovich E, Helzlsouer KJ (2012) Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy. Climacteric 15:339–349
Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107:167–180
Kirk MC, Hudis CA (2008) Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 8:155–161
Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De MJ et al (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast 17:376–381
Mouridsen HT (2006) Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin 22:1609–1621
Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108:1515–1524
Mirmirani P (2013) Managing hair loss in midlife women. Maturitas 74:119–122
Mirmirani P (2011) Hormonal changes in menopause: do they contribute to a ‘midlife hair crisis’ in women? Br J Dermatol 165(Suppl 3):7–11
Atanaskova MN, Bergfeld WF (2013) Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. Dermatol Clin 31:119–127
Ohnemus U, Uenalan M, Inzunza J, Gustafsson JA, Paus R (2006) The hair follicle as an estrogen target and source. Endocr Rev 27:677–706
Yip L, Rufaut N, Sinclair R (2011) Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol 52:81–88
Lynfield YL (1960) Effect of pregnancy on the human hair cycle. J Invest Dermatol 35:323–327
Rossi A, Iorio A, Scali E, Fortuna MC, Mari E, Maxia C et al (2013) Aromatase inhibitors induce ‘male pattern hair loss’ in women? Ann Oncol 24:1710–1711
Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M et al (1995) Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res 1:287–294
Forsythe LP, Helzlsouer KJ, MacDonald R, Gallicchio L (2012) Daytime sleepiness and sleep duration in long-term cancer survivors and non-cancer controls: results from a registry-based survey study. Support Care Cancer 20:2425–2432
Yip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G et al (2009) Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 161:289–294
Price VH (2003) Androgenetic alopecia in women. J Investig Dermatol Symp Proc 8:24–27
Liedtke S, Schmidt ME, Vrieling A, Lukanova A, Becker S, Kaaks R et al (2012) Postmenopausal sex hormones in relation to body fat distribution. Obesity (Silver Spring) 20:1088–1095
Acknowledgments
Dr. Gallicchio is a recipient of a Health Disparities Career Catalyst Grant from Susan G. Komen for the Cure (KG110356).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gallicchio, L., Calhoun, C. & Helzlsouer, K.J. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat 142, 435–443 (2013). https://doi.org/10.1007/s10549-013-2744-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-013-2744-2